Market closed
Guardant Health/$GH
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Guardant Health
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Ticker
$GH
Sector
Trading on
Industry
Health Care Providers & Services
Headquarters
Employees
2,010
Website
Guardant Health Metrics
BasicAdvanced
$5.9B
-
-$3.56
1.50
-
Price and volume
Market cap
$5.9B
Beta
1.5
52-week high
$50.89
52-week low
$16.77
Average daily volume
1.9M
Financial strength
Current ratio
4.677
Quick ratio
4.212
Long term debt to equity
-935.816
Total debt to equity
-956.735
Interest coverage (TTM)
-171.87%
Management effectiveness
Return on assets (TTM)
-16.95%
Return on equity (TTM)
-4,584.47%
Valuation
Price to revenue (TTM)
7.874
Price to book
-42.1
Price to tangible book (TTM)
-39.27
Price to free cash flow (TTM)
-21.166
Growth
Revenue change (TTM)
31.04%
Earnings per share change (TTM)
-16.96%
3-year revenue growth (CAGR)
25.52%
3-year earnings per share growth (CAGR)
-3.89%
What the Analysts think about Guardant Health
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Guardant Health stock.
Guardant Health Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Guardant Health Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Guardant Health News
AllArticlesVideos
Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR
Business Wire·3 days ago
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025
Business Wire·2 weeks ago
Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Guardant Health stock?
Guardant Health (GH) has a market cap of $5.9B as of April 25, 2025.
What is the P/E ratio for Guardant Health stock?
The price to earnings (P/E) ratio for Guardant Health (GH) stock is 0 as of April 25, 2025.
Does Guardant Health stock pay dividends?
No, Guardant Health (GH) stock does not pay dividends to its shareholders as of April 25, 2025.
When is the next Guardant Health dividend payment date?
Guardant Health (GH) stock does not pay dividends to its shareholders.
What is the beta indicator for Guardant Health?
Guardant Health (GH) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.